Heatmap of RNA-seq gene expression data showing differential gene expression in prostate cancer samples
Photomicrograph of immunofluorescence staining of a cell surface antigen in neuroendocrine prostate cancer tissue
Photomicrograph of the immunohistochemical staining of a normal human tissue microarray
Fluorescent imaging of a 384-well screening plate seeded with GFP reporter cells and treated with a small molecule inhibitor library
Live bioluminescence imaging of mice engrafted with human prostate cancer and treated with control or chimeric antigen receptor (CAR) T cells
Welcome to the Lee laboratory. Our aim is to identify molecular drivers and biological properties of prostate and bladder cancer that may be exploited for the development of new and effective treatments. In our research we employ cutting-edge technologies including mouse and human epithelial transformation systems; functional genomics; multi-omic data integration; high-throughput screening; small molecule drug discovery; and immuno-oncology to develop new approaches to stratify and treat prostate and bladder cancer.
Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. DeLucia DC, Cardillo TM, Ang LS, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, Gil da Costa RM, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK.
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON.
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON.